$XBIT News

XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers

XBiotech Appoints Jan-Paul Simard Co-CEO, Effective Oct. 23

XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

XBiotech Announces Data From Its Phase II Portion Of Multicenter TASKIN Clinical Study Meets Pre-Specifed Primary Efficacy Success Criterion Under Simon Two-Stage Design; 61.3% Participants In Vilamakitug Experimental Arm Were Alive, Surpassing Threshold Of 42, More Surviving Patients

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

XBiotech Says IND Application For V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path For U.S. Patient Enrollment

XBiotech Q1 EPS $(0.18) Up From $(0.36) YoY

XBiotech: Q4 Earnings Snapshot

XBiotech Announces John Simard To Retire As CEO, To Continue As Chairman; Sushma Shivaswamy Appointed Interim CEO

XBiotech Q3 EPS $(0.20) Down From $(0.16) YoY

XBiotech: Q3 Earnings Snapshot

XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders

XBiotech: Q2 Earnings Snapshot

XBiotech Q2 EPS $(0.06) Up From $(0.43) YoY

Here's Why We're Not Too Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Situation

XBiotech: Q1 Earnings Snapshot

XBiotech Inc.'s (NASDAQ:XBIT) largest shareholders are individual investors with 49% ownership, insiders own 35%

XBiotech Pauses Rheumatology program

XBiotech: Q2 Earnings Snapshot

XBIT Stock Earnings: XBiotech Reported Results for Q2 2024